Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein

• Published in: The American journal of tropical medicine and hygiene Vol. 84; no. 2 Suppl; pp. 35 - 42
• Main Authors: Arévalo-Herrera, Myriam, Soto, Liliana, Perlaza, Blanca Liliana, Céspedes, Nora, Vera, Omaira, Lenis, Ana Milena, Bonelo, Anilza, Corradin, Giampietro, Herrera, Sócrates
• Format: Journal Article
• Language: English
• Published: United States The American Society of Tropical Medicine and Hygiene 01-02-2011
• Subjects: Adolescent; Adult; Antibodies, Protozoan - blood; Female; Humans; Immunity, Cellular - physiology; Malaria Vaccines - immunology; Malaria, Vivax - immunology; Malaria, Vivax - prevention & control; Male; Plasmodium vivax; Plasmodium vivax - immunology; Protozoan Proteins - immunology; Vaccination; Young Adult
• ISSN: 0002-9637; 1476-1645
• DOI: 10.4269/ajtmh.2011.09-0507

Plasmodium vivax circumsporozoite (CS) protein is a leading malaria vaccine candidate. We describe the characterization of specific immune responses induced in 21 malaria-naive volunteers vaccinated with long synthetic peptides derived from the CS protein formulated in Montanide ISA 720. Both antibody- and cell-mediated immune responses were analyzed. Antibodies were predominantly of IgG1 and IgG3 isotypes, recognized parasite proteins on the immunofluorescent antibody test, and partially blocked sporozoite invasion of hepatoma cell lines in vitro. Peripheral blood mononuclear cells from most volunteers (94%) showed IFN-γ production in vitro upon stimulation with both long signal peptide and short peptides containing CD8+ T-cell epitopes. The relatively limited sample size did not allow conclusions about HLA associations with the immune responses observed. In summary, the inherent safety and tolerability together with strong antibody responses, invasion blocking activity, and the IFN-γ production induced by these vaccine candidates warrants further testing in a phase II clinical trial.